This week in charts: Brain drugs are back on venture capitalists’ minds
Neuroscience startups raised $1.9B in 2025, with $664M raised by mid-November 2026. Oyster Therapeutics secured $60M for Alzheimer's research. Cell therapy stocks saw mixed reactions to new data, with Cabaletta Bio up 5% and others like Nkarta down over 20%.
How this was made
The 30-second read
Why it matters
The mixed signals—new funding for CNS startups versus sharp declines in cell‑therapy stocks—suggest a bifurcated market sentiment within biotech.
Market read
Provides traders with fresh data on funding trends and immediate price reactions for several biotech stocks.
What to watch
The article does not discuss pipeline depth, partnership deals, or upcoming regulatory milestones that could mitigate short‑term weakness.
Background
The piece recaps recent venture capital funding in neuroscience and summarizes investor reactions to cell‑therapy data presented at a major rheumatology conference.
Ticker impact
Nkarta shares fell more than 20% between Nov. 6 and Nov. 12 after recent cell‑therapy data disappointed investors.
likely continued pressure unless new data reverses sentiment
The article reports a >20% drop tied to recent research updates.
Allogene Therapeutics shares dropped over 20% in the same period after cell‑therapy updates.
downward pressure may persist in the short term
Price decline is highlighted as a reaction to recent trial information.
Fate Therapeutics shares fell more than 20% following recent cell‑therapy conference results.
likely further downside absent positive news
The article links a >20% drop to the latest conference data.
CRISPR Therapeutics declined nearly 15% after the same conference updates.
potential continued weakness in the near term
The article notes a 15% decline tied to the conference outcomes.
Market effects
Highlights renewed VC interest in neuroscience and cautious investor reaction to cell‑therapy data, suggesting sector volatility.
Primarily U.S. biotech equities; limited broader market effect.
Signals potential shift in funding trends for CNS drug startups worldwide.
Counterpoint
Despite recent price drops, some investors may view the pull‑back as a buying opportunity if long‑term data improves.
Key entities
- companyOyster Therapeutics
London‑based CNS biotech that raised $60 million in a Series A round.
- companyCabaletta Bio
Cell‑therapy developer reporting early trial data.


